Sero and Salivary Toxoplasma Immunoglobulins: In Silico Study on Anti-genicity-Based Therapies Docked TgERP and its Dysregulatory Action on Immunoglobulins Running title: Sero and salivary toxoplasmosis and drug docking

Abstract

We aimed to assess salivary and seroprevalence of toxoplasma immunoglobulins in risky populations and evaluate drug docking targeting TgERP. A Cross-sectional study was conducted in Alexandria University hospitals' outpatient clinics. 192 participants were enrolled from September 2022 to November 2023. Anti-Toxoplasma IgG and IgM were determined in serum and salivary by ELISA. An in-Silico study examined TgERP's protein-protein interactions with pro-inflammatory cytokine receptors, anti-inflammatory cytokine, cell cycle progression regulatory proteins, a proliferation marker, and nuclear envelope integrity-related protein Lamin B1. Our findings revealed that anti-T. gondii IgG were detected in serum (66.1%) and saliva (54.7%), with 2.1% of both samples were positive for IgM. Salivary IgG had 75.59% sensitivity, 86.15% specificity, 91.40% PPV, 64.40% NPP, 79.17% accuracy and fair agreement with serum IgG. On the other hand, the sensitivity, specificity, PPV, NPV, and accuracy in detecting salivary IgM were 75.0%, 99.47%, 75.0%, 99.47%, and 98.96%. AUC 0.859 indicates good discriminatory power. Examined synthetic drugs and natural products can target specific amino acids residues of TgERP that lie at the same binding interface with Lamin B1 and Ki67, subsequently, hindering their interaction. Hence, salivary samples can be a promising diagnostic approach. In addition, this study may help alleviate toxoplasmosis' inflammatory effects.